Related Articles for PubMed (Select 18492290)

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS.

J Neuroinflammation. 2008 May 21;5:19.

PMID: 18492290 [PubMed - indexed for MEDLINE]

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.

Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, Chowdrey HS, Biggs CS, Whitton PS.

Eur J Neurosci. 2007 Jul;26(2):417-23.

PMID: 17650114 [PubMed - indexed for MEDLINE]

Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.

Neurobiol Dis. 2006 May;22(2):421-34. Epub 2006 Feb 9.

PMID: 16480889 [PubMed - indexed for MEDLINE]

Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

Ravenscroft P, Chalon S, Brotchie JM, Crossman AR.

Exp Neurol. 2004 Jan;185(1):36-46.

PMID: 14697317 [PubMed - indexed for MEDLINE]

Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.

Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT.

J Neurochem. 2007 Nov;103(3):1075-91. Epub 2007 Aug 20.

PMID: 17714448 [PubMed - indexed for MEDLINE]

Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.

Lapchak PA, Miller PJ, Collins F, Jiao S.

Neuroscience. 1997 May;78(1):61-72.

PMID: 9135089 [PubMed - indexed for MEDLINE]

Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats.

Palmer MR, Granholm AC, van Horne CG, Giardina KE, Freund RK, Moorhead JW, Gerhardt GA.

Brain Res. 2001 Jan 26;890(1):86-99.

PMID: 11164771 [PubMed - indexed for MEDLINE]

The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide.

Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS.

J Neurol Sci. 2008 Aug 15;271(1-2):131-6. Epub 2008 May 27.

PMID: 18508084 [PubMed - indexed for MEDLINE]

The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.

Jeon MY, Lee WY, Kang HY, Chung EJ.

Neurol Res. 2007 Apr;29(3):289-95.

PMID: 17509229 [PubMed - indexed for MEDLINE]

10:

Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

Oiwa Y, Yoshimura R, Nakai K, Itakura T.

Brain Res. 2002 Aug 30;947(2):271-83.

PMID: 12176170 [PubMed - indexed for MEDLINE]

11:

Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.

Glavan G, Zivin M.

Neuroscience. 2005;135(2):545-54.

PMID: 16111820 [PubMed - indexed for MEDLINE]

12:

Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA.

Exp Neurol. 2003 Sep;183(1):81-6.

PMID: 12957491 [PubMed - indexed for MEDLINE]

13:

Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.

Kääriäinen TM, García-Horsman JA, Piltonen M, Huotari M, Männistö PT.

Basic Clin Pharmacol Toxicol. 2008 Mar;102(3):300-7. Epub 2007 Oct 31.

PMID: 17973898 [PubMed - indexed for MEDLINE]

14:

Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.

Winter C, Hosmann K, Harnack D, Meissner W, Paul G, Morgenstern R, Kupsch A.

Synapse. 2006 Jul;60(1):69-80.

PMID: 16598703 [PubMed - indexed for MEDLINE]

15:

Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.

Truong L, Allbutt H, Kassiou M, Henderson JM.

Behav Brain Res. 2006 Apr 25;169(1):1-9. Epub 2006 Jan 4.

PMID: 16413939 [PubMed - indexed for MEDLINE]

16:

Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.

Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F.

J Neurochem. 2005 Apr;93(1):94-104.

PMID: 15773909 [PubMed - indexed for MEDLINE]

17:

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Winkler C, Kirik D, Björklund A, Cenci MA.

Neurobiol Dis. 2002 Jul;10(2):165-86.

PMID: 12127155 [PubMed - indexed for MEDLINE]

18:

Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease.

Abuirmeileh A, Harkavyi A, Lever R, Biggs CS, Whitton PS.

J Neuroinflammation. 2007 Jul 21;4:19.

PMID: 17659087 [PubMed - indexed for MEDLINE]

Recent Activity